P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. (23rd June 2022)

• Record Type: Journal Article
• Authors: Eyre, T. A.; Wang, M. L.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Vandenberghe, E.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; Wang, Y.; Coombs, C. C.; Flinn, I.; Lewis, D.; Le Gouill, S.; Gandhi, M.; Chay, C.; Palomba, M. L.; Woyach, J. A.; Pagel, J. M.; Lamanna, N.; Sharman, J. P.; Andorsky, D. J.; Cohen, J. B.; Barve, M. A.; Ghia, P.; Yin, M.; Zinzani, P. L.; Ujjani, C.; Koh, Y.; Izutsu, K.; Lech-Maranda, E.; Kherani, J.; Tam, C.; Sundaram, S.; Nair, B.; Tsai, D. E.; Balbas, M.; Mato, A. R.; Cheah, C. Y.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 991
• Page End: 992
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000847272.47630.ff
• Languages: English
• ISSNs: 2572-9241